Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avelumab Master Protocol: An Open-label Continuation Study for Participants Continuing From Pfizer-sponsored Avelumab Clinical Studies.

Next Previous
X
Search
Trial Profile

Avelumab Master Protocol: An Open-label Continuation Study for Participants Continuing From Pfizer-sponsored Avelumab Clinical Studies.

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary) ; Axitinib (Primary) ; Crizotinib (Primary) ; Ivuxolimab (Primary) ; Lorlatinib (Primary) ; Pemetrexed (Primary) ; Talazoparib (Primary) ; Utomilumab (Primary) ; Vidutolimod (Primary) ; Vidutolimod (Primary)
  • Indications Carcinoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; Registrational
  • Sponsors Pfizer

    • Most Recent Events

    • 03 Apr 2024 Planned End Date changed from 21 May 2025 to 30 Sep 2026.
    • 03 Apr 2024 Planned primary completion date changed from 21 May 2025 to 30 Sep 2026.
    • 03 Apr 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top